Related Experiment Video
Updated: Jul 15, 2026
Continuous-wave Thulium Laser for Heating Cultured Cells to Investigate Cellular Thermal Effects
Published on: June 30, 2017
Subthreshold Micropulse Laser for Diabetic Macular Edema: A Review
Barbara Sabal1,2, Sławomir Teper1, Edward Wylęgała1
1Chair and Clinical Department of Ophthalmology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Okregowy Szpital Kolejowy, Panewnicka 65, 40-760 Katowice, Poland.
Abstract:
Diabetic macular edema (DME) is one of the main causes of visual impairment in patients of working age. DME occurs in 4% of patients at all stages of diabetic retinopathy. Using a subthreshold micropulse laser is an alternative or adjuvant treatment of DME. Micropulse technology demonstrates a high safety profile by selectively targeting the retinal pigment epithelium. There are no standardized protocols for micropulse treatment, however, a 577 nm laser application over the entire macula using a 200 μm retinal spot, 200 ms pulse duration, 400 mW power, and 5% duty cycle is a cost-effective, noninvasive, and safe therapy in mild and moderate macular edemas with retinal thickness below 400 μm. Micropulse lasers, as an addition to the current gold-standard treatment for DME, i.e., anti-vascular endothelial growth factor (anti-VEGF), stabilize the anatomic and functional retinal parameters 3 months after the procedure and reduce the number of required injections per year. This paper discusses the published literature on the safety and application of subthreshold micropulse lasers in DME and compares them with intravitreal anti-VEGF or steroid therapies and conventional grid laser photocoagulation. Only English peer-reviewed articles reporting research within the years 2010-2022 were included.
Insights
Subthreshold micropulse laser treatment offers a safe and effective alternative for diabetic macular edema (DME). This noninvasive therapy can stabilize vision and reduce treatment frequency when used alongside or instead of standard care.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Laser Therapy
Background:
- Diabetic macular edema (DME) is a leading cause of vision loss in working-age individuals.
- DME affects approximately 4% of patients with diabetic retinopathy.
- Current treatments include anti-vascular endothelial growth factor (anti-VEGF) injections and conventional laser photocoagulation.
Purpose of the Study:
- To review the literature on subthreshold micropulse laser (SML) treatment for DME.
- To evaluate the safety and efficacy of SML as an alternative or adjuvant therapy.
- To compare SML with existing DME treatments like anti-VEGF and steroid injections.
Main Methods:
- Systematic review of English peer-reviewed articles published between 2010 and 2022.
- Focus on studies investigating SML for diabetic macular edema.
- Comparison of SML outcomes with anti-VEGF, steroid therapies, and conventional grid laser.
Main Results:
- Subthreshold micropulse laser therapy demonstrates a high safety profile by targeting the retinal pigment epithelium.
- A specific protocol (577 nm, 200 μm spot, 200 ms, 400 mW, 5% duty cycle) is effective for mild/moderate DME with retinal thickness < 400 μm.
- SML as an adjunct to anti-VEGF therapy stabilizes retinal parameters and reduces annual injection frequency.
Conclusions:
- Subthreshold micropulse laser is a cost-effective, noninvasive, and safe treatment option for DME.
- SML shows promise in stabilizing visual function and reducing treatment burden.
- Further research may establish standardized protocols for SML in DME management.
